Quantcast
Home > Quotes > CCXI
CCXI

ChemoCentryx, Inc. Common Stock (CCXI) Quote & Summary Data

$11.03
*  
0.08
0.73%
Get CCXI Alerts
*Delayed - data as of Aug. 17, 2018  -  Find a broker to begin trading CCXI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
18.5
Today's High / Low
$ 11.14 / $ 10.60
Share Volume
173,531
50 Day Avg. Daily Volume
256,744
Previous Close
$ 10.95
52 Week High / Low
$ 15.08 / $ 5.42
Market Cap
542,125,393
P/E Ratio
32.44
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ 0.34
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.68

Intraday Chart

Shares Traded

Share Volume:
173,531
50 Day Avg. Daily Volume:
256,744

P/E Ratio

P/E Ratio:
32.44
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ 0.34

Trading Range

The current last sale of $11.03 is 103.51% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 11.14 $ 15.08
 Low: $ 10.60 $ 5.42

Company Description (as filed with the SEC)

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. Our drug candidates are small molecules, which are orally administered, offering significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection. In 2016, we executed on our strategy to form an alliance with a partner that could provide upfront commitments and milestones to support the clinical development of our leading two drug candidates, avacopan and CCX140, to registration and pay us royalties upon sales in international markets, while we develop our own commercial infrastructure to sell directly in the United States.  ... More ...  


Risk Grade

Where does CCXI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 11
Open Date:
Aug. 17, 2018
Close Price:
$ 11.03
Close Date:
Aug. 17, 2018

Consensus Recommendation

Analyst Info